Trevi Therapeutics

This study tested whether an extended-release form of nalbuphine, a pain medication, can reduce chronic coughing in people with idiopathic pulmonary fibrosis (IPF). 165 participants received either different doses of the drug or a placebo for 6 weeks. The main goal was to see if …

This study tested a tablet called nalbuphine ER in 66 adults with refractory chronic cough (a cough lasting over a year with no clear cause). The goal was to see if the drug could reduce how often people coughed over 24 hours. Participants took either the drug or a placebo, then …

This early-phase study looked at how the body breaks down nalbuphine extended-release tablets in people with mild, moderate, or severe liver impairment compared to healthy volunteers. It also explored whether the drug could relieve itching in those with liver problems. The study …

This study looked at how a long-acting painkiller (nalbuphine ER) affects and is affected by two lung fibrosis drugs (pirfenidone and nintedanib) in 132 healthy adults. Researchers measured drug levels in the blood and monitored for side effects. The goal was to see if these drug…